Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taxotere and Xeloda in Metastatic Esophageal Cancer
NCT00821912Phase 2Unknown
- Sponsor
- Karolinska University Hospital
- Start
- Mar 2006
- Primary completion
- Sep 2012
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and capecitabine in esophageal cancer and gastric cardia carcinoma (GCA), sponsored by Karolinska University Hospital. Primary endpoints: Response Rate and Recommended Dose for Phase II. Status: unknown.
02
Drugs
docetaxelcapecitabine
03
Conditions
esophageal cancergastric cardia carcinoma (GCA)
Beyond the preview
Go deeper on NCT00821912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00821912.